









Markets
/
Stocks
/
nasdaq-erna
/

Eterna Therapeutics Inc

ERNA

1.670USD

-0.010-0.60%

Market hours （ET）Quotes delayed by 15 min

12.50MMarket Cap

LossP/E TTM



Eterna Therapeutics Inc

1.670

-0.010-0.60%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Eterna Therapeutics Inc

Currency: USD Updated: 2025-11-04

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is high. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Eterna Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

223 / 407

Overall Ranking

433 / 4616

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Eterna Therapeutics Inc Highlights

StrengthsRisks

Eterna Therapeutics Inc. is a life science company committed to realizing the potential of messenger ribonucleic acid (RNA) (mRNA) cell engineering to provide patients with transformational new medicines. The Company has in-licensed a portfolio of over 100 patents covering key mRNA cell engineering technologies, including technologies for mRNA cell reprogramming, mRNA gene editing, the NoveSlice and UltraSlice gene-editing proteins, and the ToRNAdo mRNA delivery system (collectively mRNA technology platform). Its mRNA gene-editing technology is designed to delete, insert and repair deoxyribonucleic acid (DNA) sequences in living cells, which may be useful for correcting disease-causing mutations, making cells resistant to infection and degenerative disease, modulating the expression of immunoregulatory proteins to enable the generation of durable allogeneic cell therapies, and engineering immune cells to more effectively fight cancer.

Growing

The company is in a growing phase, with the latest annual income totaling USD 582.00K.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 582.00K.

Undervalued

The company’s latest PE is -0.09, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 49.81K shares, decreasing 55.52% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 0.00 shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-04

The company's current financial score is 6.52, which is lower than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 43.16%.

Score

Industry at a Glance

Previous score

6.52

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.42

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.67

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.46

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Eterna Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-11-04

The company’s current valuation score is 5.97, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -0.09, which is -97.88% below the recent high of -0.00 and -31.57% above the recent low of -0.12.

Score

Industry at a Glance

Previous score

5.97

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 223/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-04

There is no earnings forecast score for this company; the Biotechnology & Medical Research industry's average is 8.00.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-04

The company’s current price momentum score is 7.06, which is higher than the Biotechnology & Medical Research industry's average of 6.41. Sideways: Currently, the stock price is trading between the resistance level at 2.66 and the support level at 0.90, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.09

Change

-0.03

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.120

Buy

RSI(14)

62.500

Neutral

STOCH(KDJ)(9,3,3)

34.990

Neutral

ATR(14)

0.240

High Vlolatility

CCI(14)

75.201

Neutral

Williams %R

67.235

Sell

TRIX(12,20)

1.052

Sell

StochRSI(14)

2.578

Sell

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

1.754

Sell

MA10

1.477

Buy

MA20

1.378

Buy

MA50

1.306

Buy

MA100

1.594

Buy

MA200

0.949

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-04

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.15. The latest institutional shareholding proportion is 0.65%, representing a quarter-over-quarter decrease of 98.95%. The largest institutional shareholder is The Vanguard, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 100.00% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Cherington (Charles)

2.78M

+104.20%

Freebird Partners LP

414.10K

Halpern (John D)

390.45K

Denny George P Iii

332.71K

+1.02%

IAF, LLC

315.78K

+45.50%

Regolith Capital Investments LP

222.88K

Purchase Capital LLC

66.67K

Singer (Nicholas Jason)

54.00K

Geode Capital Management, L.L.C.

20.07K

+2.72%

Corient Private Wealth LLC

17.52K

-0.01%

Risk Assessment

Currency: USD Updated: 2025-11-04

The company’s current risk assessment score is 2.00, which is lower than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 6.23. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.